Biologically active synthetic nanoparticle constructs and methods of use thereof

US10100332B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10100332-B2
Application numberUS-201414913804-A
CountryUS
Kind codeB2
Filing dateAug 25, 2014
Priority dateAug 23, 2013
Publication dateOct 16, 2018
Grant dateOct 16, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

This application discloses the compositions comprising biologically active synthetic nanoparticle constructs and methods of use thereof to modify gene expression including transcriptional activation and transcriptional repression.

First claim

Opening claim text (preview).

What is claimed is: 1. A biologically active synthetic nanoparticle construct comprising: i. a biologically inert substrate; ii. a plurality of single copies of DNA binding domains; iii. a plurality of single copies of nuclear localization signals; and iv. a plurality of single copies of transcriptional activation domains, wherein the plurality of DNA binding domains are each individually covalently attached to a surface of the biologically inert substrate, wherein the plurality of nuclear localization signals are each individually covalently attached to the surface of the biologically inert substrate, wherein the plurality of transcriptional activation domains are each individually covalently attached to the surface of the biologically inert substrate, wherein the plurality of transcriptional activation domains consist of peptides comprising D-amino acids, wherein the plurality of DNA binding domains comprise one of oligonucleotides, small molecules, and peptide nucleic acids, and wherein the ratios of nuclear localization signals and DNA binding domains to activation domains are effective to ensure sufficient nuclear uptake and provide a binding affinity essentially equivalent to naturally-occurring DNA binding proteins. 2. The biologically active synthetic nanoparticle construct of claim 1 wherein the biologically inert substrate is selected from the group consisting of: gold nanoparticles, magnetic nanoparticles, magnetic-core shell nanoparticles, silica nanoparticles, mesoporous nanoparticles, quantum dots, supramolecular nanoparticles, and polymer-based nanoparticles. 3. The biologically active synthetic nanoparticle construct of claim 1 wherein the plurality of DNA binding domains is selected from the group consisting of: hairpin polyamides, zinc finger domains, triple forming oligonucleotides, transcription activator-like effectors, oligonucleotide analogs, locked-nucleic acids, peptide nucleic acids, and combinations thereof. 4. The biologically active synthetic nanoparticle construct of claim 3 , wherein the plurality of DNA binding are hairpin polyamides, and wherein the hairpin polyamides comprise at least one N-methyl-imidazole moiety or at least one N-methyl pyrrole moiety, or combinations thereof, arranged sequentially on said polyamide to bind a target gene. 5. The biologically active synthetic nanoparticle construct of claim 1 wherein the plurality of nuclear localization signals are attached to the surface of the biologically inert substrate by crosslinking molecules and wherein the plurality of DNA binding domains are attached to the surface of the biologically inert substrate by crosslinking molecules. 6. The biologically active synthetic nanoparticle construct of claim 1 wherein the plurality of nuclear localization signals are derived from a SV-40 antigen, derived form an HIV-1 antigen, or derived from the group consisting of: TAT, Penetratin, MAP, Transportin/TP10, VP22, MPG, Pep1, pVEC, YTA2, YTA4, M918, CADY, and combinations thereof. 7. The biologically active synthetic nanoparticle construct of claim 1 wherein the plurality of nuclear localization signals follow the Chelsky sequence. 8. The biologically active synthetic nanoparticle construct of claim 1 wherein the plurality of nuclear localization signals are non-classical. 9. The biologically active synthetic nanoparticle construct of claim 1 wherein the biologically inert substrate comprises a gold nanoparticle. 10. A biologically active synthetic nanoparticle construct comprising: i. a biologically inert substrate; ii. a plurality of single copies of DNA binding domains; iii. a plurality of single copies of nuclear localization signals; and iv. a plurality of single copies of transcriptional repression domains, wherein the plurality of DNA binding domains are each individually covalently attached to a surface of the biologically inert substrate, wherein the plurality of nuclear localization signals are each individually covalently attached to the surface of the biologically inert substrate, wherein the plurality of transcriptional repression domains are each individually covalently attached to the surface of the biologically inert substrate, wherein the plurality of transcriptional repression domains consist of peptides comprising D-amino acids, wherein the plurality of DNA binding domains comprise one of oligonucleotides, small molecules, and peptide nucleic acids, and wherein the ratios of nuclear localization signals and DNA binding domains to transcriptional repression domains are effective to ensure sufficient nuclear uptake and provide a binding affinity essentially equivalent to naturally-occurring DNA binding proteins. 11. The biologically active synthetic nanoparticle of claim 10 wherein the biologically inert substrate is selected from the group consisting of: gold nanoparticles, magnetic nanoparticles, magnetic-core shell nanoparticles, silica nanoparticles, mesoporous nanoparticles, quantum dots, supramolecular nanoparticles, and polymer-based nanoparticles. 12. The biologically active synthetic nanoparticle construct of claim 10 wherein the plurality of DNA binding domains is selected from the group consisting of: hairpin polyamides, zinc finger domains, triple forming oligonucleotides, transcription activator-like effectors, oligonucleotide analogs, locked-nucleic acids, peptide nucleic acids, and combinations thereof. 13. The biologically active synthetic nanoparticle construct of claim 12 wherein the plurality of DNA binding are hairpin polyamides, and wherein the hairpin polyamides comprise at least one N-methyl-imidazole moiety or at least one N-methyl pyrrole moiety, or combinations thereof, arranged sequentially on said polyamide to bind a target gene. 14. The biologically active synthetic nanoparticle construct of claim 10 wherein the plurality of nuclear localization signals are attached to the surface of the biologically inert substrate by crosslinking molecules and wherein the plurality of DNA binding domains are attached to the surface of the biologically inert substrate by crosslinking molecules. 15. The biologically active synthetic nanoparticle construct of claim 10 wherein the plurality of nuclear localization signals are derived from a SV-40 antigen, derived form an HIV-1 antigen, or derived from the group consisting of: TAT, Penetratin, MAP, Transportin/TP10, VP22, MPG, Pep1, pVEC, YTA2, YTA4, M918, CADY, and combinations thereof. 16. The biologically active synthetic nanoparticle construct of claim 10 wherein the plurality of nuclear localization signals follow the Chelsky sequence. 17. The biologically active synthetic nanoparticle construct of claim 10 wherein the plurality of nuclear localization signals are non-classical. 18. The biologically active synthetic nanoparticle construct of claim 10 wherein the biologically inert substrate comprises a gold nanoparticle.

Assignees

Inventors

Classifications

  • C12N15/87Primary

    Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation · CPC title

  • Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source · CPC title

  • the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb · CPC title

  • Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10100332B2 cover?
This application discloses the compositions comprising biologically active synthetic nanoparticle constructs and methods of use thereof to modify gene expression including transcriptional activation and transcriptional repression.
Who is the assignee on this patent?
Univ Rutgers
What technology area does this patent fall under?
Primary CPC classification C12N15/87. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Oct 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).